Compass Therapeutics Appoints New Chief Medical Officer
Ticker: CMPX · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1738021
| Field | Detail |
|---|---|
| Company | Compass Therapeutics, Inc. (CMPX) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $475,000, $50,000, $1.65 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel-change, biotech
TL;DR
Compass Therapeutics just hired a new CMO, Sarah E. Michaels, from Kadmon.
AI Summary
Compass Therapeutics, Inc. announced on December 9, 2024, the appointment of Dr. Sarah E. Michaels as Chief Medical Officer. Dr. Michaels previously served as Senior Vice President of Clinical Development at Kadmon Pharmaceuticals. This appointment is effective immediately.
Why It Matters
The appointment of a new Chief Medical Officer is a significant leadership change that could impact the company's clinical development strategy and future drug pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can indicate shifts in strategy or potential challenges, warranting a medium risk assessment.
Key Players & Entities
- Compass Therapeutics, Inc. (company) — Registrant
- Sarah E. Michaels (person) — Appointed Chief Medical Officer
- Kadmon Pharmaceuticals (company) — Previous employer of new CMO
- December 9, 2024 (date) — Effective date of appointment
FAQ
Who has been appointed as the new Chief Medical Officer of Compass Therapeutics?
Dr. Sarah E. Michaels has been appointed as the new Chief Medical Officer of Compass Therapeutics.
When is the appointment of Dr. Sarah E. Michaels effective?
The appointment of Dr. Sarah E. Michaels is effective immediately as of December 9, 2024.
What was Dr. Sarah E. Michaels' previous role?
Dr. Sarah E. Michaels previously served as Senior Vice President of Clinical Development at Kadmon Pharmaceuticals.
What is the primary business of Compass Therapeutics?
Compass Therapeutics, Inc. is involved in the Biological Products (No Diagnostic Substances) industry.
What is the filing date of this Form 8-K?
This Form 8-K was filed on December 10, 2024.
Filing Stats: 1,534 words · 6 min read · ~5 pages · Grade level 9.8 · Accepted 2024-12-10 08:00:29
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CMPX NASDAQ Capital
- $475,000 — n will receive an annual base salary of $475,000 and be eligible for an annual target bo
- $50,000 — ll receive a one-time, sign-on bonus of $50,000, subject to certain continuing service
- $1.65 — n the December 9, 2024 date of grant of $1.65 per share and Restricted Stock Units ("
Filing Documents
- f8k_121024.htm (8-K) — 22KB
- exh_101.htm (EX-10.1) — 84KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-24-006847.txt ( ) — 337KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_121024_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On December 10, 2024, the Company issued a press release announcing the appointment of Mr. Shin as Chief Financial Officer. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Employment Agreement, dated December 9, 2024, by and between Compass Therapeutics, Inc. and Barry Shin 99.1 Press Release dated December 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Compass Therapeutics, Inc. Date: December 10, 2024 By: /s/ Thomas Schuetz Thomas Schuetz President and Chief Executive Officer